Author + information
- Chong Keat Tan,
- Mohd Kamal Mohd Arshad,
- Hee Hwa Ho,
- Fahim H. Jafary,
- Jason K.K. Loh,
- Timothy Watson and
- Paul J.L. Ong
Background: Implanting a single long stent avoids stent overlap, geographical miss and allows possible cost savings. Our study reviewed procedural safety and clinical outcome at 1 year of patients with long coronary lesions (Type C) treated with 48mm Xience Xpedition everolimus drug eluting stent (EES).
Methods: Patients with 48mm EES implanted during coronary angioplasty between 2013 to 2015 were followed up for 1 year. Major adverse cardiac events (MACE) includes cardiac death, myocardial infarction (MI), target lesion revascularization (TLR) and stent thrombosis (ST). All patients were given 1 year of dual antiplatelet therapy.
Results: 80 EES were implanted in 76 patients (58 males, mean age 59 years). 29 (38%) patients had diabetes mellitus, 43 (57%) hypertension, 42 (55%) hyperlipidaemia and 37 (49%) smokers. Indication was ST elevation MI in 19 (25%) patients, non-ST elevation MI in 23 (30%), unstable angina in 8 (11%) and stable angina in 26 (34%). Mean stent diameter was 2.96 +0.30 mm. Mean number of non-compliant balloon for post-dilatation was 1.4. In hospital MACE was 1.32% with 1 stent thrombosis on day 2 requiring TLR. At 1 year, MACE rate was 3 (3.95%) with 2 cardiac deaths (2.63%), 1 MI (1.32%) and 2 ST (2.63%).
Conclusions: Our study showed that the 48mm EES appeared safe and effective at 1 year with low clinical events in this cohort of high risk patients.
Poster Contributions Poster Hall, Hall C
Saturday, March 18, 2017, 3:45 p.m.-4:30 p.m.
Session Title: Coronary Intervention: Drug Eluting Stent & Scaffolds
Abstract Category: 21. Interventional Cardiology: Coronary Intervention: Devices
Presentation Number: 1240-136
- 2017 American College of Cardiology Foundation